The ECFS-CTN cannot guarantee that the information provided here is comprehensive. Please go to the ClinicalTrials.gov link for detailed and up-to-date information on study background, eligibility criteria, study design, outcome measures, study status, participating sites, sponsor contact information and timelines.
You can also contact the CTN coordinating centre for additional information: ECFS-CTN@uzleuven.be
Study Name on ClinicalTrials.gov (link is external) |
Safety, Pharmacokinetics and Pharmacodynamics Study of Inhaled QBW276 in Patients With Cystic Fibrosis |
---|---|
Study Drug | QBW276 |
Type of Study Drug | Restore Airway Surface Liquid |
Study Title | A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Inhaled QBW276 in Patients With Cystic Fibrosis |
Study Phase | 1 and 2 |
Study Sponsor | Novartis |
Participating ECFS-CTN sites | Please contact ecfs-ctn@uzleuven.be for most recent sitelist |
Age | 18 years and older |